Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002717 · ClinicalTrials.gov registry record · Phase 3
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
A Phase 3 study of Ovarian Cancer and Primary Peritoneal Cavity Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 324
- Enrollment target
- 20
- Study locations
NCT00002717 is a Phase 3 study of Ovarian Cancer and Primary Peritoneal Cavity Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 324 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00002717, a Phase 3 study of Ovarian Cancer and Primary Peritoneal Cavity Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 324 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for ovarian or peritoneal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of paclitaxel plus cisplatin in treating patients who have residual disease after surgery to remove stage III or stage IV ovarian cancer or primary peritoneal cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG paclitaxel
Study Locations (20)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Chao Family Comprehensive Cancer Center - Orange
- Women's Cancer Center - Palo Alto
Illinois
- Rush-Presbyterian-St. Luke's Medical Center - Chicago
- University of Chicago Cancer Research Center - Chicago
- CCOP - Central Illinois - Decatur
District of Columbia
- Vincent T. Lombardi Cancer Research Center, Georgetown University - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
Alabama
- University of Alabama Comprehensive Cancer Center - Birmingham
Colorado
- University of Colorado Cancer Center - Denver
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Emory University Hospital - Atlanta - Atlanta
Hawaii
- MBCCOP - Hawaii - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 1996-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002717
The ClinicalTrials.gov registry entry for NCT00002717 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (55% lower). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which cisplatin is the first listed.
NCT00002717 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Illinois, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00002717 about?
NCT00002717 is a clinical study titled "Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for ovarian or peritoneal cancer. PURPOSE: Randomized phas...
What is the current status of trial NCT00002717?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 324 participants. The study started on 1996-03.
What conditions does trial NCT00002717 study?
This clinical trial studies the following conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer.
What interventions are being tested in trial NCT00002717?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00002717?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002717 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.